Proteomics

Dataset Information

0

Serum proteome profiling across different stages of myxomatous mitral valve disease in domestic dogs


ABSTRACT: Development and progression of myxomatous mitral valve disease (MMVD) in domestic dogs is unpredictable and pathobiology still unclear. The American College of Veterinary Internal Medicine (ACVIM) perceived that mayor improvement in management of diseased dogs would be timely diagnosis, especially detection of transition from MMVD stage B1 into B2. Thus, in this study we compared by tandem mass tag (TMT) protocol and mass spectrometry (MS) acquired quantitative proteome profiles of serum collected from healthy (control) (N=12) and dogs diagnosed with different stages of naturally occurring MMVD: B1 (N=13), B2 (N=12) and C (N=13). Prior to proteomic analysis dogs were distinguished into experimental categories based on echocardiography results. Serum biochemistry and concentrations of three cardiac biomarkers (galectin-3, suppression of tumorigenicity 2 and asymmetric dimethylarginine) were performed to obtain better characterization of healthy/control group and MMVD cases.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Bos Taurus (bovine)

TISSUE(S): Blood Serum

DISEASE(S): Cardiovascular System Disease

SUBMITTER: Dina Rešetar Maslov  

LAB HEAD: Prof. Vladimir Mrljak

PROVIDER: PXD038475 | Pride | 2023-05-10

REPOSITORIES: Pride

altmetric image

Publications

Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs.

Rešetar Maslov Dina D   Farkaš Vladimir V   Rubić Ivana I   Kuleš Josipa J   Beletić Anđelo A   Beer Ljubić Blanka B   Šmit Iva I   Mrljak Vladimir V   Torti Marin M  

International journal of molecular sciences 20230412 8


Canine myxomatous mitral valve disease (MMVD) is similar to Barlow's form of MMVD in humans. These valvulopathies are complex, with varying speeds of progression. We hypothesized that the relative abundances of serum proteins would help identify the consecutive MMVD stages and discover new disease pathways on a systemic level. To identify distinction-contributing protein panels for disease onset and progression, we compared the proteomic profiles of serum from healthy dogs and dogs with differen  ...[more]

Similar Datasets

2022-10-18 | PXD017263 | Pride
2020-05-18 | PXD015951 | Pride
2023-06-27 | PXD039022 | Pride
2022-08-29 | PXD017454 | Pride
2020-05-26 | PXD017129 | Pride
2021-05-26 | PXD022595 | Pride
2021-11-25 | PXD024921 | Pride
2020-10-19 | PXD018893 | Pride
2018-08-20 | PXD009399 | Pride
2023-10-30 | PXD041129 | Pride